Cord Blood News Volume 10.21 | May 31 2018

TOP STORY

Single-Cell Analysis Identifies a CD33⁺ Subset of Human Cord Blood Cells with High Regenerative Potential

From a multi-parameter analysis of the molecular features of very primitive human cord blood cells that display long-term cell outputs in vitro and in immunodeficient mice, scientists identified a prospectively separable CD33⁺CD34⁺CD38⁻CD45RA⁻CD90⁺CD49f⁺ phenotype with serially transplantable, but diverse, cell output profiles. [Nat Cell Biol] Abstract

(Ranked by impact factor of the journal)

The Interleukin-3 Receptor CD123 Targeted SL-401 Mediates Potent Cytotoxic Activity against CD34⁺CD123⁺ Cells from Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients and Healthy Donors

Researchers report indiscriminate killing of CD123⁺ normal and acute myeloid leukemia/myelodysplastic syndrome cells by SL-401, a diphtheria toxin interleukin-3 fusion protein. In addition to primary samples, studies on normal cord blood and healthy marrow showed that SL-401 has activity against normal hematopoietic progenitors. [Haematologica] Abstract | Full Article

Which Is More Important for the Selection of Cord Blood Units for Hematopoietic Cell Transplantation: The Number of CD34‐Positive Cells or Total Nucleated Cells?

Using the registry database of Japan Society for Haematopoietic Cell Transplantation and the Japanese Data Centre for Haematopoietic Cell Transplantation, the authors retrospectively identified 1917 adult and adolescent recipients with leukemia or lymphoma who underwent their first transplant from a single unit of cord blood with <2.5 × 107 total nucleated cells (TNC)/kg between 2006 and 2014, and categorized them into 12 groups according to TNC doses. [Br J Haematol] Full Article

Validation of Reference and Identity-Defining Genes in Human Mesenchymal Stem Cells Cultured under Unrelated Fetal Bovine Serum Batches for Basic Science and Clinical Application

Investigators evaluated in stem cells isolated from bone marrow (BMMSCs) and umbilical cord-blood (CBMSCs) the effects of independently collected fetal bovine serum batches on both twelve commonly used reference genes and a selected panel of thirty-eight genes crucial for MSC definition in both research and clinical settings. [Stem Cell Rev] Abstract

The Impact of Cytokine Gene Polymorphisms on the Outcome of HLA Matched Sibling Hematopoietic Stem Cell Transplantation

Graft-versus-host disease is the major complication of allogeneic hematopoietic stem cell transplantation (HSCT); cytokines are recognized as important mediators in its pathogenesis. Researchers investigated the role of cytokine gene polymorphisms on HSCT outcome. [Cytokine] Abstract

Umbilical Cord Mesenchymal Stem Cells Conditioned Medium Promotes Aβ25-35 Phagocytosis by Modulating Autophagy and Aβ-Degrading Enzymes in BV2 Cells

Umbilical cord mesenchymal stem cells conditioned medium (ucMSCs-CM) inhibited the proliferation and decreased cell death of BV2 cells induced by Aβ25-35. ucMSCs-CM also promoted the phagocytosis of Aβ25-35 by BV2 cells and changed the expression of autophagy-related proteins LC3, Beclin-1, and p62. [J Mol Neurosci] Abstract

Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges

Administration of MSCs to diseased hearts improves cardiac function and reduces scar size. These effects occur via the stimulation of endogenous repair mechanisms, including regulation of immune responses, tissue perfusion, inhibition of fibrosis, and proliferation of resident cardiac cells, although rare events of transdifferentiation into cardiomyocytes and vascular components are also described in animal models. [Mol Ther] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Nohla Announces EHA Abstract Acceptance on Dilanubicel (NLA101) Off-the-Shelf Cell Therapy Showing Excellent Long-Term Survival Outcomes

Nohla Therapeutics announced the online availability of an abstract that has been selected for presentation. The abstract summarizes long-term follow-up data showing that Nohla’s dilanubicel cell therapy significantly improved hematopoietic recovery with no patients experiencing transplant-related mortality, leading to an 86% disease-free and overall survival rate in patients undergoing a cord blood transplant. [Press release from Nohla Therapeutics discussing research to be presented at the 23^rd Congress of European Hematology Association Annual Conference, Stockholm] Press Release

Oncolytics Biotech^® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN^® with Keytruda^®, Velcade^® and Dexamethasone

Oncolytics Biotech^® Inc. announced a collaboration with the Keck School of Medicine of University of Southern California (USC) using pelareorep in combination with Keytruda^®, Velcade^® and dexamethasone, to treat multiple myeloma. [Oncolytics Biotech^® Inc.] Press Release

GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy

GlycoMimetics, Inc. announced it had signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under the terms of the CRADA, GlycoMimetics will collaborate with both the NCI and the Alliance for Clinical Trials in Oncology to conduct a randomized, controlled clinical trial testing the addition of GMI-1271 to a standard cytarabine/daunorubicin regimen in older adults with previously untreated acute myelogenous leukemia (AML) who are suitable for intensive chemotherapy. [GlycoMimetics, Inc.] Press Release

U.S. FDA Grants Priority Review to Astellas’ New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Astellas Pharma Inc. announced that the FDA has accepted, with Priority Review, the company’s New Drug Application for gilteritinib for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation as detected by an FDA-approved test. [Astellas Pharma Inc.] Press Release

After Brexit, Can British Science Have Its Cake and Eat It, Too?

Nearly two years after Britons voted to leave the European Union, Brexit’s impact on European science is finally coming into focus. Prime Minister Theresa May announced that the United Kingdom wants to take part in the next EU research-funding program, set to be worth almost €100 billion (US$116 billion). [Nature News] Editorial

Max Planck Scientists Criticize Handling of Animal-Rights Charges against Leading Neuroscientist

Scientists at one of Germany’s leading neuroscience institutes say that their employer, the Max Planck Society, is failing in its responsibility to defend the institute’s scientists against efforts by animal-rights activists to disrupt research. [Nature News] Editorial

NEW British Society for Haemostasis and Thrombosis (BSHT) Annual Meeting 2018
November 8-9, 2018
Coventry, United Kingdom

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellowship – Myeloid Tumors (St. Jude Children’s Research Hospital)

NEW Postdoctoral Positions – Cell Biology (Children’s Hospital of Philadelphia)

Assistant, Associate, or Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – 3D Chromatin Architecture, Epigenetics and Metabolism (Josep Carreras Leukaemia Research Institute)

Postdoctoral Research Scholar – Hematologic Malignancies (Washington University School of Medicine)

Postdoctoral Fellow – B-Cell Lymphoma (University of Texas Health Science Center)

Postdoctoral Fellow – Hematopoiesis and Leukemia (University of Pennsylvania)

Research Fellow – Hematology, Blood Disorders and Stem Cell Biology (New York Blood Center)

Postdoctoral Fellow – Molecular and Translational Cancer Biology (Thomas Jefferson University)

Postdoctoral Position – Hematology (Yale Cancer Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.